High-Tech Treatments Threaten Medicare Budget, Trustee Says

Law360, New York (June 20, 2013, 2:17 PM EDT) -- Medicare’s financial future has brightened amid a lull in development of blockbuster drugs and advanced medical devices, but costly clouds are on the horizon as innovation proceeds in genomic therapy, stem cell research and other high-tech fields, one of the program’s two public trustees said Thursday.

Robert D. Reischauer told a congressional panel that the decline in “major new technologies” was a key factor in last month’s forecast that Medicare’s solvency has been extended to 2026, two years longer than previously projected.

The pause in introduction...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.